1-4 of 4
John M. Ford
Close
Sort by
Journal Articles

Switching from Deferoxamine (Desferal ® , DFO) to Deferasirox (Exjade ® ) Maintains Effective Control of Iron Levels in Patients with Thalassemia Major (TM)

Maria Domenica Cappellini, Antonis Kattamis, Christos Kattamis, John B Porter, John M Ford, Martha Rodriguez, Lisa Rojkjaer, Antonio Piga
Journal: Blood
Blood (2008) 112 (11): 5416.
https://doi.org/10.1182/blood.V112.11.5416.5416
Published: 2008
Journal Articles

Safety of Deferasirox (Exjade ® ) in Patients with Transfusion-Dependent Anemias and Iron Overload Who Achieve Serum Ferritin Levels <1000 Ng/Ml during Long-Term Treatment

John B Porter, Antonio Piga, Alan Cohen, John M Ford, Janet Bodner, Lisa Rojkjaer, Maria Domenica Cappellini
Journal: Blood
Blood (2008) 112 (11): 5423.
https://doi.org/10.1182/blood.V112.11.5423.5423
Published: 2008
Journal Articles

Evaluation of Deferasirox (Exjade®, ICL670) Therapy in Patients with Transfusional Iron Overload Who Achieve Serum Ferritin (SF) ≤1000 ng/mL in Long-Term Studies.

Maria Domenica Cappellini, Elliott Vichinsky, John M. Ford, Bertrand Rabault, John Porter
Journal: Blood
Blood (2007) 110 (11): 3795.
https://doi.org/10.1182/blood.V110.11.3795.3795
Published: 2007
Journal Articles

Impact of Dose Adjustments on Serum Ferritin (SF) Levels during Long-Term Treatment with Once-Daily, Oral Deferasirox (Exjade®, ICL670).

John B. Porter, Alan R. Cohen, John M. Ford, Maria Domenica Cappellini
Journal: Blood
Blood (2007) 110 (11): 2778.
https://doi.org/10.1182/blood.V110.11.2778.2778
Published: 2007